Leukemia treatment requires a personalized approach that balances efficacy with safety. Dasanat 20 Mg is a low-dose formulation of dasatinib intended for patients who need a reduced dosage due to age, body weight, organ dysfunction or sensitivity to therapy. Dasatinib is a second‑generation tyrosine kinase inhibitor that targets the BCR‑ABL fusion protein and SRC family kinases to inhibit proliferation of Philadelphia chromosome–positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cells. By offering a 20 mg strength, physicians can titrate the medication more precisely, optimizing therapeutic benefit while minimizing side effects.
The tablet should be taken exactly as prescribed by your oncologist, typically once daily, with or without food. Swallow the tablet whole; do not split, crush or chew it, as this may affect absorption. Because dasatinib interacts with many medications and foods, avoid grapefruit products and inform your healthcare team about all prescriptions, over‑the‑counter drugs and supplements you use. Do not take antacids or proton pump inhibitors within a few hours of dasatinib, as they may reduce its absorption.
Even at a lower dose, dasatinib may cause side effects. Common reactions include nausea, vomiting, diarrhea, abdominal discomfort, headache, muscle aches, rash and fluid retention such as peripheral edema or pleural effusion. Blood counts can drop, leading to anemia, neutropenia or thrombocytopenia; regular laboratory monitoring is essential. Rare but serious adverse events include pulmonary arterial hypertension, QT interval prolongation, bleeding, liver toxicity and infections. Seek immediate medical care if you experience chest pain, shortness of breath, coughing up blood, or severe bruising.
Dasanat 20 mg should not be used during pregnancy or breastfeeding, as it can harm a developing fetus. Use reliable contraception during treatment and for a period after stopping therapy. Patients with heart disease, uncontrolled hypertension, bleeding disorders or severe liver impairment need careful assessment before use. Because dosing with targeted therapies is complex, never alter your dose or discontinue treatment without consulting your oncologist. With individualized dosing and monitoring, Dasanat 20 mg provides a flexible option for managing CML and Ph+ ALL when standard doses are not tolerated.
The tablet should be taken exactly as prescribed by your oncologist, typically once daily, with or without food. Swallow the tablet whole; do not split, crush or chew it, as this may affect absorption. Because dasatinib interacts with many medications and foods, avoid grapefruit products and inform your healthcare team about all prescriptions, over‑the‑counter drugs and supplements you use. Do not take antacids or proton pump inhibitors within a few hours of dasatinib, as they may reduce its absorption.
Even at a lower dose, dasatinib may cause side effects. Common reactions include nausea, vomiting, diarrhea, abdominal discomfort, headache, muscle aches, rash and fluid retention such as peripheral edema or pleural effusion. Blood counts can drop, leading to anemia, neutropenia or thrombocytopenia; regular laboratory monitoring is essential. Rare but serious adverse events include pulmonary arterial hypertension, QT interval prolongation, bleeding, liver toxicity and infections. Seek immediate medical care if you experience chest pain, shortness of breath, coughing up blood, or severe bruising.
Dasanat 20 mg should not be used during pregnancy or breastfeeding, as it can harm a developing fetus. Use reliable contraception during treatment and for a period after stopping therapy. Patients with heart disease, uncontrolled hypertension, bleeding disorders or severe liver impairment need careful assessment before use. Because dosing with targeted therapies is complex, never alter your dose or discontinue treatment without consulting your oncologist. With individualized dosing and monitoring, Dasanat 20 mg provides a flexible option for managing CML and Ph+ ALL when standard doses are not tolerated.
0